NeuroSense to Strengthen PrimeC Canadian ALS Submission With New NfL Data
NeuroSense Therapeutics (NRSN) plans to include new neurofilament light chain (NfL) data in its New Drug Submission (NDS) for PrimeC, its ALS treatment, to Health Canada. The filing, now targeted for March 2027, aims to strengthen the application with additional biomarker evidence. If approved, PrimeC could address approximately 4,000 Canadians living with ALS. The company is also advancing discussions with potential commercialization partners for Canada.





